ArticleBMC medical imaging2025
PDC-DETR: a Parallel Dilated Convolutional Detection Transformer for preliminary screening of multiple macular degeneration.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Current diagnostic approaches for macular degeneration in optical coherence tomography (OCT) images often lead to misdiagnosis due to their limited ability to capture the disease’s multiscale and irregular features. We present PDC-DETR, a Parallel Dilated Convolutional Detection Transformer, which introduces three major innovations for accurate and efficient macular degeneration analysis. First, a Parallel Feature-Optimized Attention Pyramid Network (PFOAPN) enables simultaneous modeling of global context and local details through multi-scale feature pathways. Second, a novel Wise-MPDIoU loss dynamically adjusts to variations in image quality while improving lesion localization accuracy. Third, the lightweight design ensures real-time clinical applicability, requiring only 38.2 MB parameters and 58.5 GFLOPs, while achieving 94.1% accuracy across five macular degeneration categories at 71 FPS. This study establishes a new benchmark for automated OCT-based retinal disease detection, providing both high diagnostic accuracy and practical clinical deployment potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.